Orthofix (OFIX) Earnings & Revenues Beat Estimates In Q4
Zacks Investment Research | Feb 26, 2018 09:31PM ET
Orthofix International N.V. (NASDAQ:OFIX) reported fourth-quarter 2017 adjusted earnings per share (EPS) of 52 cents from continuing operations. The figure is ahead of the Zacks Consensus Estimate by a couple of cents. Adjusted earnings improved 23.8% year over year, primarily on strong sales growth at the company’s Biologics and Spine Fixation strategic business units (SBU).
Excluding one-time items, net income from continuing operations in the fourth quarter came in at 8 cents per share, showing a remarkable year-over-year improvement over the net loss from continuing operations of 29 cents.
Sales Details
Orthofix’s fourth-quarter sales improved 7.7% (6.1% at constant exchange rate or CER) to $116.9 million. The figure also beat the Zacks Consensus Estimate of $112 million by 4.4%.
Sales were primarily driven by a better-than-expected performance by the company’s all four SBUs with significant contributions from Biologics and Spine Fixation.
SBU Details
For the fourth quarter, the company posted BioStim sales of $49.8 million, reflecting 4.1% (same at CER) growth from the prior-year period. Biologics SBU sales totaled $16.9 million, up 10.7% (same at CER) from the year-ago quarter. This upside resulted from strong sales of Trinity Elite allograft, banking on an expanded distributor network.
Extremity Fixation sales were $29.1 million in the quarter under review, showing an 8.4% improvement (up 2.2% at CER) from fourth-quarter 2016. The company particularly realized strong revenue growth from the outside U.S. Extremity Fixation's stocking distribution.
Orthofix International N.V. Price, Consensus and EPS Surprise
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.